The news flow from Sinovac Biotech Ltd. was very positive this week. Healive™, a hepatitis A vaccine, was chosen by the Beijing Medicine Bidding Center as one of two inactivated hepatitis A vaccines in pre-filled syringes for its hepatitis A vaccination program. A few days earlier, Sinovac’s Q3 financial report showed the fortunes of Sinovac to be very much on the upswing. Total sales jumped 141% year-over-year and net income climbed to $2.2 million, a 23-fold jump from the $93,000 recorded in 2006. More details...

Stock Symbols: (AMEX: SVA) (NYSE: GSK)